Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Autolus Therapeutics (AUTL) EBT Margin: 2017-2025

Historic EBT Margin for Autolus Therapeutics (AUTL) over the last 6 years, with Sep 2025 value amounting to -370.79%.

  • Autolus Therapeutics' EBT Margin fell 113883.00% to -370.79% in Q3 2025 from the same period last year, while for Sep 2025 it was -430.66%, marking a year-over-year decrease of 109145.00%. This contributed to the annual value of -2,165.36% for FY2024, which is 1010802.00% up from last year.
  • Autolus Therapeutics' EBT Margin amounted to -370.79% in Q3 2025, which was down 63.26% from -227.12% recorded in Q2 2025.
  • Over the past 5 years, Autolus Therapeutics' EBT Margin peaked at 768.03% during Q3 2024, and registered a low of -16,684,745.76% during Q3 2021.
  • For the 3-year period, Autolus Therapeutics' EBT Margin averaged around -9,529.26%, with its median value being -370.79% (2025).
  • Its EBT Margin has fluctuated over the past 5 years, first crashed by 1,667,443,069bps in 2021, then spiked by 1,668,294,028bps in 2022.
  • Quarterly analysis of 5 years shows Autolus Therapeutics' EBT Margin stood at -1,662.13% in 2021, then surged by 146,791bps to -194.22% in 2022, then soared by 45,045bps to 256.22% in 2023, then plummeted by 9,040,795bps to -90,151.72% in 2024, then tumbled by 113,883bps to -370.79% in 2025.
  • Its EBT Margin stands at -370.79% for Q3 2025, versus -227.12% for Q2 2025 and -756.36% for Q1 2025.